Patent details

Basic Information

Publication number:

92401

Type:

SPC

SPC Type:

Medical

Basic Patent Number:

EP019572387

Legal Status:

Active

Application number:

92401

First applicant's nationality:

Procedural language:

French

Marketing Authorization

1

Marketing Authorization Number:

2013110425 - Treclinax

Marketing Authorization Type:

Marketing Authorization Date:

01/11/2013

Marketing Authorization Status:

Accepted

Marketing Authorization Country:

Luxembourg (LU)

2

Marketing Authorization Number:

PA1332/043/001 - Treclinac 1% w/w / 0.025% w/w Gel

Marketing Authorization Type:

Marketing Authorization Date:

22/03/2013

Marketing Authorization Status:

Accepted

Marketing Authorization Country:

Dates

Filing date:

18/03/2014

First Marketing Authorization date:

22/03/2013

Grant date:

19/05/2014

Activation date:

24/07/2021

Publication date:

19/05/2014

Lapsed date:

Expiration date:

Renunciation date:

Revocation date:

Annulment date:

Basic SPC Expiration:

24/07/2026

SPC Extension Expiration:

24/07/2026

Rejection date:

Withdrawal date:

Owner

From:

18/03/2014

 

 

Name:

Dow Pharmaceutical Sciences Inc.

Address:

1330a Redwood Way, Petaluma CA 94954-6542, United States (US)

Agent

Name:

OFFICE FREYLINGER S.A.

From:

18/03/2014

Address:

Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)

To:

Inventor

1

Name:

DOW Debra, A.

Address:

United States (US)

2

Name:

DOW Gordon, J.

Address:

United States (US)

3

Name:

LATHROP Robert, W.

Address:

United States (US)

Publication

Bulletin

Bulletin Heading:

SPC3

Bulletin edition number:

2021/09

Publication date:

03/08/2021

Description:

Section E : Supplementary Protection certificates entered into force – IA publication

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

05/05/2025

Last Annual Fee Paid Number:

25

Last Annual Fee Paid Amount:

450 Euro

Payer:

OFFICE FREYLINGER S.A.

Filing date	Document type	Number of pages